Effect of Sildenafil Citrate on the Male Sexual Experience Assessed with the Sexual Experience Questionnaire: A Multicenter, Double‐Blind, Placebo‐Controlled Trial with Open‐Label Extension

LeRoy A. Jones; Ira W. Klimberg; James G. McMurray; Rebecca Padula; Li‐Jung Tseng; Vera J. Stecher

doi:10.1111/j.1743-6109.2008.00879.x

Effect of Sildenafil Citrate on the Male Sexual Experience Assessed with the Sexual Experience Questionnaire: A Multicenter, Double‐Blind, Placebo‐Controlled Trial with Open‐Label Extension

Journal of Sexual Medicine ◽

10.1111/j.1743-6109.2008.00879.x ◽

2008 ◽

Vol 5 (8) ◽

pp. 1955-1964 ◽

Cited By ~ 18

Author(s):

LeRoy A. Jones ◽

Ira W. Klimberg ◽

James G. McMurray ◽

Rebecca Padula ◽

Li‐Jung Tseng ◽

...

Keyword(s):

Sexual Experience ◽

Controlled Trial ◽

Sildenafil Citrate ◽

Open Label ◽

Double Blind ◽

Double Blind Placebo ◽

Open Label Extension ◽

Experience Questionnaire

Download Full-text

Interleukin-2 diphtheria fusion protein (dab486il-2) in refractory rheumatoid arthritis a double-blind, placebo-controlled trial with open-label extension

Arthritis & Rheumatism ◽

10.1002/art.1780380902 ◽

1995 ◽

Vol 38 (9) ◽

pp. 1177-1186 ◽

Cited By ~ 49

Author(s):

Larry W. Moreland ◽

K. Lea Sewell ◽

David E. Trentham ◽

R. Pat Bucy ◽

William F. Sullivan ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Fusion Protein ◽

Controlled Trial ◽

Interleukin 2 ◽

Open Label ◽

Double Blind ◽

Double Blind Placebo ◽

Refractory Rheumatoid Arthritis ◽

Open Label Extension

Download Full-text

Faculty Opinions recommendation of Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1115446.571475 ◽

2008 ◽

Author(s):

Lars Klareskog ◽

Anca Catrina

Keyword(s):

Controlled Trial ◽

Open Label ◽

Double Blind ◽

Double Blind Placebo ◽

Open Label Extension ◽

Axial Spondylarthritis

Download Full-text

Safety and efficacy of pregabalin in adolescents with fibromyalgia: a randomized, double-blind, placebo-controlled trial and a 6-month open-label extension study

Pediatric Rheumatology ◽

10.1186/s12969-016-0106-4 ◽

2016 ◽

Vol 14 (1) ◽

Cited By ~ 19

Author(s):

Lesley M. Arnold ◽

◽

Kenneth N. Schikler ◽

Lucinda Bateman ◽

Tahira Khan ◽

...

Keyword(s):

Controlled Trial ◽

Extension Study ◽

Open Label ◽

Double Blind ◽

Safety And Efficacy ◽

Double Blind Placebo ◽

Open Label Extension

Download Full-text

Adjunctive zonisamide therapy in the long-term treatment of children with partial epilepsy: Results of an open-label extension study of a phase III, randomized, double-blind, placebo-controlled trial

Epilepsia ◽

10.1111/epi.12548 ◽

2014 ◽

Vol 55 (4) ◽

pp. 568-578 ◽

Cited By ~ 24

Author(s):

Renzo Guerrini ◽

Anna Rosati ◽

Kate Bradshaw ◽

Luigi Giorgi

Keyword(s):

Controlled Trial ◽

Term Treatment ◽

Partial Epilepsy ◽

Phase Iii ◽

Open Label ◽

Double Blind ◽

Double Blind Placebo ◽

Long Term Treatment ◽

Open Label Extension

Download Full-text

Efficacy of add-on mirtazapine on clinical and neuropsychologic parameters in schizophrenic patients treated with conventional antipsychotics: a double-blind, placebo-controlled trial with an open-label extension phase

http://isrctn.org/> ◽

10.1186/isrctn00721331 ◽

2012 ◽

Author(s):

Grigori Joffe

Keyword(s):

Controlled Trial ◽

Extension Phase ◽

Open Label ◽

Double Blind ◽

Double Blind Placebo ◽

Conventional Antipsychotics ◽

Open Label Extension ◽

Schizophrenic Patients

Download Full-text

A randomized, double-blind, placebo-controlled trial and open-label extension study to evaluate the efficacy and safety of pregabalin in the treatment of neuropathic pain associated with human immunodeficiency virus neuropathy

Pain ◽

10.1016/j.pain.2014.05.027 ◽

2014 ◽

Vol 155 (10) ◽

pp. 1943-1954 ◽

Cited By ~ 30

Author(s):

David M. Simpson ◽

Andrew S.C. Rice ◽

Birol Emir ◽

Jaren Landen ◽

David Semel ◽

...

Keyword(s):

Human Immunodeficiency Virus ◽

Neuropathic Pain ◽

Controlled Trial ◽

Extension Study ◽

Efficacy And Safety ◽

Open Label ◽

Double Blind ◽

Double Blind Placebo ◽

Immunodeficiency Virus ◽

Open Label Extension

Download Full-text

THU0366 Efficacy of Adalimumab in Patients with Axial Spondyloarthritis: Results of an Investigator-Initiated 12-Weeks Randomized Double-Blind Placebo Controlled Trial with a 12 Weeks Open-Label Extension Phase

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2013-eular.894 ◽

2013 ◽

Vol 72 (Suppl 3) ◽

pp. A289.2-A289 ◽

Cited By ~ 1

Author(s):

S. J. Pedersen ◽

IJ Sørensen ◽

AG Loft ◽

JS Hindrup ◽

G Thamsborg ◽

...

Keyword(s):

Axial Spondyloarthritis ◽

Controlled Trial ◽

Extension Phase ◽

Open Label ◽

Double Blind ◽

Double Blind Placebo ◽

Open Label Extension

Download Full-text

Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: Results of a twelve‐week randomized, double‐blind, placebo‐controlled trial followed by an open‐label extension up to week fifty‐two

Arthritis & Rheumatism ◽

10.1002/art.23606 ◽

2008 ◽

Vol 58 (7) ◽

pp. 1981-1991 ◽

Cited By ~ 208

Author(s):

Hildrun Haibel ◽

Martin Rudwaleit ◽

Joachim Listing ◽

Frank Heldmann ◽

Robert L. Wong ◽

...

Keyword(s):

Controlled Trial ◽

Open Label ◽

Double Blind ◽

Double Blind Placebo ◽

Open Label Extension ◽

Axial Spondylarthritis

Download Full-text

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

The Lancet Neurology ◽

10.1016/s1474-4422(18)30069-3 ◽

2018 ◽

Vol 17 (5) ◽

pp. 405-415 ◽

Cited By ~ 85

Author(s):

Raju Kapoor ◽

Pei-Ran Ho ◽

Nolan Campbell ◽

Ih Chang ◽

Aaron Deykin ◽

...

Keyword(s):

Multiple Sclerosis ◽

Disease Progression ◽

Controlled Trial ◽

Progressive Multiple Sclerosis ◽

Open Label ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Secondary Progressive ◽

Open Label Extension

Download Full-text

Faculty Opinions recommendation of Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1115446.793498406 ◽

2014 ◽

Author(s):

David Daikh

Keyword(s):

Controlled Trial ◽

Open Label ◽

Double Blind ◽

Double Blind Placebo ◽

Open Label Extension ◽

Axial Spondylarthritis

Download Full-text